Biogen Inc (BIIB)
298.90
-2.95 (-0.98%)
USD |
NASDAQ |
Dec 02, 16:00
298.82
-0.08 (-0.03%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 43.04B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 30.80% |
| Valuation | |
| PE Ratio | 15.22 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.226 |
| Price to Book Value | 3.369 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.4915 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 54.78% |
News
Headline
Wire
Time (ET)
SA Breaking News
12/02 08:12
Yahoo
12/02 07:55
SA Breaking News
12/01 11:24
MT Newswires
12/01 10:11
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/03/2023* | 08:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 02/03/2023* | -- | Results | Q4 2022 | -- | 3.49 | -- | |
| 10/25/2022 | -- | Results | Q3 2022 | 4.77 | 4.13 | 15.50% | |
| 10/25/2022 | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 07/20/2022 | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 07/20/2022 | -- | Results | Q2 2022 | 5.25 | 4.07 | 29.01% | |
| 05/03/2022 | 08:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 05/03/2022 | -- | Results | Q1 2022 | 3.62 | 4.36 | -17.04% |
*Estimated Date/Time
Earnings
Profile
Edit
| Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021. |
| URL | http://www.biogen.com |
| Investor Relations URL | https://investors.biogen.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Feb. 03, 2023 (est.) |
| Last Earnings Release | Oct. 25, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of December 02, 2022.
Fundamentals
| Revenue (TTM) | 10.36B |
| Total Expenses (TTM) | 7.404B |
| Net Income (TTM) | 2.865B |
| Total Assets (Quarterly) | 24.85B |
| Total Liabilities (Quarterly) | 12.09B |
| Shareholders Equity (Quarterly) | 12.78B |
| Cash from Operations (TTM) | 2.398B |
| Cash from Investing (TTM) | 1.605B |
| Cash from Financing (TTM) | -1.730B |
Ratings
Profile
Edit
| Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021. |
| URL | http://www.biogen.com |
| Investor Relations URL | https://investors.biogen.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Feb. 03, 2023 (est.) |
| Last Earnings Release | Oct. 25, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| VPMCX | 2.527B USD | 4.20% |
| IBB | 337.96M USD | 3.89% |
| POAGX | 235.16M USD | 3.49% |
| MOAT | 226.58M USD | 3.47% |
| VHCOX | 586.52M USD | 3.46% |
| VPCCX | 335.83M USD | 3.20% |
| POGRX | 208.97M USD | 3.16% |
| VGHCX | 1.409B USD | 3.02% |
| XBI | 120.85M USD | 1.56% |
| IWS | 91.25M USD | 0.68% |
| IWR | 123.01M USD | 0.44% |
| RSP | 96.58M USD | 0.29% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| BIIB Tweets |